Patent granted: Advancing innovation in…
We are proud to announce that our products have been granted a patent by…
Please be aware that this website is not intended for consumers, as the information provided herein does not refer to finished commercial products that are generally available to the public.
The claims made refer to ingredients only and may not comply with Regulation (EC) No. 1924/2006, the Swiss Federal Act on Foodstuffs and Utility Articles (and related Ordinance), the Swiss Ordinance of the Internal Affairs Department on Information concerning Foodstuffs and Cosmetics, or other relevant regulations in your country. Any claims or statements about the products relating to their health benefits have not been evaluated by the Food and Drug Administration (FDA) and should not be considered a substitute for professional medical advice, diagnosis, or treatment. Any of the ingredients are intended to diagnose, treat, cure, or prevent any disease or health condition.
This website is accessible from various countries around the world. Therefore, it may include statements or information that are not applicable to your country or region.
We are proud to announce that our products have been granted a patent by…
Effective from 1 December 2025 Linnea releases its updated Environmental Social & Governance (ESG)…
We’re pleased to share that Linnea’s updated GMP certificate and MIA have now been…
We’re proud to announce the first-ever isolation of a previously unknown cannabinoid, cannabizetol (CBGD),…
We are proud to announce that our THC:CBD combinations have reached 6-month ICH stability.…
Effective from 3 October 2025 Our updated Human Rights Policy 2025 is now live,…
We are thrilled to announce that Linnea’s GMP certificate just got a major upgrade…
Endorsed by the Swiss Federal Office for Energy in July 2025 This plan is…
Last week, we took another important step forward by submitting our updated Communication on…
We are pleased and proud to announce that our company’s Decarbonization plan has been…
The installation of our new THC distillation unit marks a major milestone in bringing…
Following our previously published findings on the anti-inflammatory potential of CBD-rich extracts in psoriasis…
Exciting developments are underway in the world of nanomedicine, as researchers unveil a pioneering…
After giving its contribution to the revision of the Ph. Eur. monograph on Cannabis…
Vivalto Partners, a French private equity firm dedicated to healthcare, is pleased to announce…
Linnea is proud to announce its participation as the Swiss frontrunner partner in the…
Linnea SA has been a pioneer in the Cannabinoid active pharmaceutical ingredient (API) industry…
In October 2024, Linnea team was thrilled to exhibit at CPHI Milan, the premier…
The European Directorate for the Quality of Medicines & Healthcare (EDQM) has issued a…
Linnea is proud to comply with the new CBD monograph issued by the European…
Effective from March 2021 Linnea reaffirms its commitment to strong ethical standards, responsible behavior,…